论文部分内容阅读
大量证据表明,钙拮抗剂有两个以上受体:尼群地平(Nitrendipine,ND)样受体;维拉帕米(异搏定,VP)样受体和可能是地尔硫草(Diltiazem,DT)受体。它们分别可用氚标记加以研究。二氢吡啶类药物作用于尼群地平受体的结合位点;而维拉帕米及其类似物和已在欧洲上市的利多氟嗪(Lidoflazine)、氟桂嗪(Fl-
There is ample evidence that calcium antagonists have more than two receptors: Nitrendipine (ND) -like receptors; Verapamil (Verapamil, VP) -like receptors and possibly Diltiazem DT) receptor. They are available tritium markers to be studied. Dihydropyridines act on the binding site of nitrendipine receptors; and verapamil and its analogues are also available in the European markets of Lidoflazine, Fl-